Cat No.
CEI-0171
Description
LY2228820 can inhibit p38 MAPK with IC50 of 7 nM.
CAS No.
862507-23-1
Targets
p38 MAPK
Chemical Name
5-(2-tert-butyl-4-(4-fluorophenyl)-1H-imidazol-5-yl)-3-neopentyl-3H-imidazo[4,5-b]pyridin-2-amine dimethanesulfonate
M.Wt
612.74
Purity
>99%
Solubility
DMSO 35 mg/mL Water 123 mg/mL Ethanol 3 mg/mL
Storage
2 years at -20centigrade Powder
In vitro
LY2228820 signi?cantly inhibited phosphorylation of HSP27, a downstream target of p38MAPK. LY2228820 alone does not inhibit the growth of MM cell lines, it synergistically enhanced cytotoxicity and apoptosis triggered by bortezomib. LY2228820 modulates the BM microenvironment of MM cells, inhibits in vitro osteoclastogenesis induced by M-CSF and sRANKL.
In vivo
LY2228820 blocks in vivo osteoclastogenesis in a SCID-hu MM model.
